安旭生物
(688075)
| 流通市值：11.46亿 | | | 总市值：45.85亿 |
| 流通股本：3177.08万 | | | 总股本：1.27亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 129,406,701.97 | 503,357,076.78 | 316,140,350.49 | 204,374,691.1 |
| 营业收入 | 129,406,701.97 | 503,357,076.78 | 316,140,350.49 | 204,374,691.1 |
| 二、营业总成本 | 112,894,368.8 | 442,709,355.79 | 215,762,189.99 | 98,764,549.95 |
| 营业成本 | 74,913,346.43 | 290,445,148.75 | 158,532,795.8 | 97,115,692.13 |
| 税金及附加 | 1,996,951.09 | 8,559,858.24 | 5,139,855.93 | 3,986,394.2 |
| 销售费用 | 8,524,969.77 | 42,834,420.98 | 31,662,720.47 | 20,025,859.98 |
| 管理费用 | 10,862,380.1 | 66,532,117.54 | 43,477,393.01 | 28,860,107.63 |
| 研发费用 | 19,840,217.39 | 105,274,988.63 | 68,008,768.32 | 48,338,587.79 |
| 财务费用 | -3,243,495.98 | -70,937,178.35 | -91,059,343.54 | -99,562,091.77 |
| 其中:利息费用 | - | - | - | 36,569.44 |
| 其中:利息收入 | - | - | -12,971,951.18 | 10,491,006.79 |
| 加:公允价值变动收益 | 6,095,879.37 | -54,801,692.97 | -31,159,070.34 | -16,299,647.12 |
| 加:投资收益 | 38,691,313.65 | 140,106,777.14 | 117,560,589.06 | 78,426,293.18 |
| 资产处置收益 | -175,791.22 | 7,162,046.65 | 6,172,251.09 | 6,176,114.79 |
| 资产减值损失(新) | 230,121.79 | -23,966,156.66 | 2,600,595.25 | - |
| 信用减值损失(新) | - | 273,692.25 | 383,417.77 | 2,984,013.02 |
| 其他收益 | 13,159,386.79 | 38,061,974.23 | 15,188,750 | 10,800,485 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0.01 |
| 四、营业利润 | 74,513,243.55 | 167,484,361.63 | 211,124,693.33 | 187,697,400.03 |
| 加:营业外收入 | 49,952.16 | 165,168.17 | 678,692.73 | 611,523.95 |
| 减:营业外支出 | 237.72 | 23,832,570.99 | 5,201,562.61 | 115,064.05 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 74,562,957.99 | 143,816,958.81 | 206,601,823.45 | 188,193,859.93 |
| 减:所得税费用 | 4,228,237.87 | 2,852,149.4 | 20,238,909.43 | 21,692,428.03 |
| 六、净利润 | 70,334,720.12 | 140,964,809.41 | 186,362,914.02 | 166,501,431.9 |
| 持续经营净利润 | 70,334,720.12 | 140,964,809.41 | 186,362,914.02 | 166,501,431.9 |
| 归属于母公司股东的净利润 | 70,190,798.47 | 141,553,680.39 | 186,839,773.09 | 166,775,151.34 |
| 少数股东损益 | 143,921.65 | -588,870.98 | -476,859.07 | -273,719.44 |
| (一)基本每股收益 | 0.55 | 1.11 | 1.47 | 1.31 |
| (二)稀释每股收益 | 0.55 | 1.11 | 1.47 | 1.31 |
| 八、其他综合收益 | 35,730.24 | -157,052.72 | 705,904.12 | 709,039.65 |
| 归属于母公司股东的其他综合收益 | 35,730.24 | -157,052.72 | 705,904.12 | 709,039.65 |
| 九、综合收益总额 | 70,370,450.36 | 140,807,756.69 | 187,068,818.14 | 167,210,471.56 |
| 归属于母公司股东的综合收益总额 | 70,226,528.71 | 141,396,627.67 | 187,545,677.21 | 167,484,191 |
| 归属于少数股东的综合收益总额 | 143,921.65 | -588,870.98 | -476,859.07 | -273,719.44 |
| 公告日期 | 2024-04-30 | 2024-04-30 | 2023-10-31 | 2023-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |